MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Metrics to compare | MIRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMIRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.2x | −3.5x | −0.5x | |
PEG Ratio | −0.07 | 0.00 | 0.00 | |
Price/Book | 19.7x | 0.9x | 2.6x | |
Price / LTM Sales | - | 0.7x | 3.3x | |
Upside (Analyst Target) | - | 315.3% | 43.3% | |
Fair Value Upside | Unlock | −10.0% | 6.9% | Unlock |